Expression of membrane-associated lymphotoxin/tumor necrosis factor-beta on human lymphokine-activated killer cells. 1991

Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
Second Department of Surgery, Ehime University School of Medicine.

A membrane-associated lymphotoxin (LT)-related molecule was detected on human lymphokine-activated killer (LAK) cells by flow cytometric analysis. Kinetic analysis revealed that the LT antigenicity on LAK cells appeared at 9 h after the beginning of culture and was maintained thereafter. By autoradiography, the molecular weight of membrane LT was estimated to be 31 kD and/or 62 kD.

UI MeSH Term Description Entries
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015979 Killer Cells, Lymphokine-Activated Cytolytic lymphocytes with the unique capacity of killing natural killer (NK)-resistant fresh tumor cells. They are INTERLEUKIN-2-activated NK cells that have no MAJOR HISTOCOMPATIBILITY COMPLEX restriction or need for antigen stimulation. LAK cells are used for ADOPTIVE IMMUNOTHERAPY in cancer patients. LAK Cells,Lymphokine-Activated Killer Cells,Cell, LAK,Cell, Lymphokine-Activated Killer,Cells, LAK,Cells, Lymphokine-Activated Killer,Killer Cell, Lymphokine-Activated,Killer Cells, Lymphokine Activated,LAK Cell,Lymphokine Activated Killer Cells,Lymphokine-Activated Killer Cell

Related Publications

Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
April 1992, Neurologia medico-chirurgica,
Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
December 1992, Journal of immunology (Baltimore, Md. : 1950),
Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
April 1992, Lymphokine and cytokine research,
Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
September 1994, Japanese journal of cancer research : Gann,
Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
July 1994, [Hokkaido igaku zasshi] The Hokkaido journal of medical science,
Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
September 1988, Proceedings of the National Academy of Sciences of the United States of America,
Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
January 1994, Journal of clinical immunology,
Y Abe, and M Miyake, and A Horiuchi, and S Kimura, and Y Hitsumoto
January 1990, Cancer immunology, immunotherapy : CII,
Copied contents to your clipboard!